|Bid||218.41 x 800|
|Ask||218.77 x 1100|
|Day's range||217.91 - 225.34|
|52-week range||205.10 - 305.21|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||54.19|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Nov 2012|
|1y target est||N/A|
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.